<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160133</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-09-67</org_study_id>
    <nct_id>NCT01160133</nct_id>
  </id_info>
  <brief_title>To Evaluate the Physical Effects of Systane(R) Lubricant Eye Drops Compared to Refresh Tears(R) Lubricant Eye Drops</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-site, randomized, investigator-masked study to evaluate the physical effects
      of Systane(R) versus Refresh Tears(R) in subjects with moderate to severe dry eye. It is a
      6-week, perspective, randomized, active-controlled, investigator-masked, parallel group
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate physical effects of Systane and Refresh Tears in subjects to moderate to severe dry eye.</measure>
    <time_frame>Baseline to visit 3 (Day 42)</time_frame>
    <description>This is a descriptive study in which changes from baseline in Tear Break up Time, corneal staining, and the Ocular Symptoms Questionnaire will be evaluated by treatment group at every visit. The outcome of the IDEEL questionnaire at Visit 3 will be compared to Visit 1 by treatment group; the results of treatment satisfaction questionnaires will be tabulated by treatment at Visit 3.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Systane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systane Lubricant Eye Drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Refresh Tears</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Refresh Tears Lubricant Eye Drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Systane</intervention_name>
    <description>Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)</description>
    <arm_group_label>Systane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Refresh Tears</intervention_name>
    <description>Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)</description>
    <arm_group_label>Refresh Tears</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be 18 years of age or older of any sex and any race, with a score of at
             least 2 (some of the time) on the subject-assessed Symptom Eligibility question.

          -  A sodium fluorescein corneal staining sum of â‰¥ 3 in either eye.

          -  A best-corrected visual acuity of 0.6 logMAR or better in each eye as assessed using
             an ETDRS chart.

        Exclusion Criteria:

          -  A history or evidence of ocular or intraocular surgery in either eye within the past 6
             months.

          -  Lasik patients can be included if lasik surgery was greater than 6 months prior to the
             initiation of the study.

          -  A history of intolerance or hypersensitivity to any component of the study
             medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vasan Eye Care Hospital</name>
      <address>
        <city>Saidapet</city>
        <state>Channai</state>
        <zip>600 015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>April 7, 2012</last_update_submitted>
  <last_update_submitted_qc>April 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systane</keyword>
  <keyword>Refresh Tears</keyword>
  <keyword>Dry Eye</keyword>
  <keyword>Moderate to Severe Dry Eye</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

